Waldenström macroglobulinemia (WM) is a low-grade B-cell clonal disorder characterized by lymphoplasmacytic bone marrow involvement associated with monoclonal immunoglobulin M. Although WM remains to be an incurable disease with a heterogeneous clinical course, the recent discovery of mutations in the MYD88 and CXCR4 genes further enhanced our understanding of its pathogenesis. Development of new therapies including monoclonal antibodies, proteasome inhibitors, and Bruton tyrosine kinase inhibitors have made the management of WM increasingly complex. Treatment should be tailored to the individual patient while considering many clinical factors. The clinical outcomes are expected to continue to improve, given the emergence of novel therapeutics and better understanding of the underlying pathogenesis.
Introduction
Waldenström macroglobulinemia (WM) is defined as lymphoplasmacytic lymphoma-associated (LPL) with monoclonal immunoglobulin M (IgM). WM represents approximately 2% of all hematologic malignancies with 1000 to 1500 new cases per year in the United States. 1 WM is more common in men and Caucasians with a median age of 60 to 70 years. 1 WM is classified as an indolent disease, with previous studies reporting a median survival about 5 years. Studies have evaluated mutations in WM cases, and 2 candidate mutations were found, including myeloid differentiation primary response 88 (MYD88) and/or C-X-C chemokine receptor type 4 (CXCR4) mutations. 2 As such, novel therapies are under development to target mutant proteins or their downstream effects to further improve treatment outcomes. A variety of factors should be considered for the treatment of patients with WM, including necessity for rapid cytoreduction, control of viscosity-related symptoms, adverse effects of treatment, comorbid conditions, eligibility for stem cell transplantation (SCT), and, finally, goal of treatment. We reviewed and summarized the current understandings of WM pathogenesis and treatment options in various clinical settings.
Methods
We searched PubMed, EMBASE, and the Cochrane databases as well as annual meeting abstracts up to September 1, 2016 for randomized clinical trials, phase I/II clinical studies, and retrospective studies. Search key words included Waldenström macroglobulinemia, WM, lymphoplasmacytic lymphoma, and LPL. Three reviewers (S.Y., R.C.B., F.A.) mutually agreed upon the selected articles. We focused on the prospective studies, and emphasis was given to the regimens that are commonly used in daily practice.
Clinical Presentation
WM can manifest with a variety of symptoms, which could be classified into 2 major categories: neoplasmic organ involvementand IgM paraprotein-related symptoms. Patients may present with nonspecific B-symptoms such as fever, weight loss, fatigue, and drenching night sweat from bone marrow (BM) involvement as well as lymphadenopathy or hepatosplenomegaly. BM involvement commonly causes anemia, which is exacerbated by hepcidin secretion by lymphoplasmacytic cells. 3 IgM paraprotein can cause depositions in the organs, cryoglobulinemia, peripheral neuropathy (PN), and hyperviscosity syndrome. About 20% to 25% of patients with WM develop PN from sensory demyelination related to antimyelin-associated glycoprotein (MAG) antibody. Hyperviscosity symptoms such as visual changes and neurologic and cardiovascular compromise commonly occur when the IgM protein level is above 30 to 40 g/L.
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Diagnosis
The diagnosis of WM is based on clinicopathologic features. 5, [7] [8] [9] BM examination in WM should demonstrate at least 10% of infiltration by small lymphocytes with lymphoplasmacytic features or lymphoplasmacytic lymphoma. Dutcher bodies, which are intranuclear vacuoles containing IgM protein, are common in WM. 5, 7, 8 Elevated IgM should be present to diagnose WM.
Immuno-phenotype in WM is typically positive for CD19, CD20, CD22, CD25, CD27, CD38, CD79a, FMC7, and surface/cytoplasmic IgM, and negative for CD5, CD10, CD11c, CD23, and CD103, although there can be some variations. 4 These immunophenotypic features are important to differentiate WM from other hematologic malignances such as multiple myeloma (MM), mantle cell lymphoma, chronic lymphocytic leukemia, and marginal zone lymphoma (Table 1) .
Pathogenesis
There are many cytogenetic abnormalities and mutations frequently found in patients with WM. Common abnormalities are del(6q) (50%), somatic hyper-mutation in IGHV, t(9;14)(p13;q32) (50%), and trisomy 4 (20%). MYD88 and C-X-C chemokine receptor type 4 WHIM (CXCR4 WHIM ) somatic mutations were found in more than 90% and 30% to 35% of patients with WM, respectively, and have been shown to play a pivotal role in WM tumorigenesis. MYD88 is an adaptor protein for toll-like receptor 4 (TLR-4) and interleukin-1 and -2 receptors (IL-1R and IL-2R). Once bound, MYD88 is either activated directly by these receptors, or is activated via interaction with TIR domain-containing adaptor protein (TIRAP) and Bruton tyrosine kinase (BTK), leading to the activation of the NF-kB pathway. [10] [11] [12] A somatic point mutation of the MYD88 substituting amino acid leucine to proline at position 265 (MYD88 L265P ) results in pro-survival "gain of function." 10 Wholegenome sequencing in patients with WM and patients with non-IgM secreting LPL demonstrated MYD88 L265P to be the most common somatic variant (91%), followed by CXCR4 (27%).
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The MYD88 L265P mutation was rare or absent in the IgM MGUS (10%-60%), 2,14 marginal zone lymphoma (7%), 2 chronic lymphocytic leukemia (3%), 15 and MM (0%), 2, 11 suggesting MYD88 L265P as a potential biomarker that could be used to differentiate WM from other pathologies that share common morphologic and clinical features. CXCR4 is a G-protein coupled receptor and was shown to play a pivotal role in cytokine release and chemotaxis.
16 CXCR4 mutations are similar to the warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome, which result in permanent activation of CXCR4 by stromal derived factor-1 alpha (SDF-1a). WM cell migration and adhesions were shown to be inhibited by CXCR4 knockdown, CXCR4 inhibitor, and G i protein inhibitor treatments in response to SDF-1, indicating the essential role that CXCR4 plays in homing of WM cells. 16 WM cells were also shown to express VLA-4, another chemokine receptor, which directly interacts with CXCR4 to activate AKT and MAPK pathways, leading to cell survival and evasion of apoptosis. 16 Whole genome sequencing identified CXCR4 somatic mutations (S344 frameshift, S339 frameshift, T311 frameshift, S338 nonsense) in 27% of patients with WM. 13 These mutations include the regulatory carboxyl domain, resulting in the impairment of internalization and prolonged activation of CXCR4. 12, 17 As such, patients harboring CXCR4 S338 mutations were shown to have an inferior response to ibrutinib. 18 Although the majority of cases of WM are of sporadic origin, familial WM also exists (about 20%). 16 Kristinsson et al showed that there is an excess risk among patients with first degree familial members with WM, suggesting an autosomal dominant or co-dominant inheritance pattern. 16 Familial WM has been correlated to an younger age and a higher BM involvement at the time of diagnosis. 19 In addition, familial disease has an increased risk of death (hazard ratio [HR], 1.3) compared with sporadic disease, 20 and it was shown to be an independent risk factor for disease progression (HR, 0.554). 21 Patients with familial WM have inferior treatment responses, shorter time to progression, and shorter time to next therapy with rituximab therapy compared with patients with sporadic WM, although they have improved outcomes with bortezomib-containing regimens. 21 
Management
Indications for Treatment
WM is an insidious lymphoproliferative disease that shares many similarities with low-grade non-Hodgkin lymphomas (NHLs). Its indolent manner therefore lends itself to close monitoring before any active treatment is needed. 22 
Management of Hyperviscosity
Hyperviscosity syndrome secondary to elevated IgM leads to decreased blood flow, compromising microcirculation including the central nervous system and heart. In patients with hyperviscosity-related symptoms such as blurry vision, headache, papilledema, stupor/coma, chest pain, or ischemic changes, plasmapheresis should be initiated promptly for IgM removal from the serum. Red blood cell transfusion should be avoided because it can increase blood viscosity and precipitate symptoms. 23 Plasmapheresis is only a temporary measure, and patients should proceed to systemic treatment to prevent the recurrence of symptoms. 23 
Evidence in Treatment-naive Patients
The paucity of randomized trials in WM limits the level of evidence supporting a particular approach. As a result, there is no standard care established for WM, and the management options are mainly based on phase II clinical trials and expert opinion. Common treatment regimens include combination therapy utilizing anti-CD20 monoclonal antibodies, nucleoside analogs (fludarabine, cladribine, bendamustine), alkylating agents (cyclophosphamide, chlorambucil), and proteasome inhibitors (bortezomib, carfilzomib) ( One of the caveats with rituximab use as monotherapy was the slower time to response. Accordingly, it is preferred in patients with minimal symptoms who do not need rapid response. A transient increase in IgM serum levels is common with monotherapy. IgM flare usually occurs in 1 to 4 months of treatment, and it could exacerbate anti-MAG neuropathy and hyperviscosity symptoms. Also, careful interpretation is needed to differentiate IgM flare from lack of response or disease progression. Plasmapheresis is suggested in patients with high IgM (>4000 mg/dL) or hyperviscosity symptoms to prevent IgM flare. 28 Of note, late intolerance to rituximab occurs in 10% to 15% of cases. Ofatumumab, an anti-CD20 monoclonal antibody that binds to a distinct epitope from rituximab binding site, also showed an ORR of 67% in one study that included 9 (24%) treatment-naive patients with WM, indicating that ofatumumab may be an alternative option for rituximabintolerant patients. 29 Based on its efficacy as a single agent, rituximab was further evaluated in combination with other agents including alkylating agents, purine analogues, and bendamustine. In comparison to monotherapy, combination therapies were shown to rapidly reduce the IgM level. As such, they are commonly used in patients who have hepatosplenomegaly or significant BM infiltration, requiring rapid cytoreduction. The most commonly used regimens are rituximab, cyclophosphamide, and dexamethasone (RCyD); rituximab, bortezomib, and dexamethasone (RVD); and bendamustine and rituximab (BR), although there are other combinations that have shown efficacy in WM.
In a prospective study with 72 treatment-naive patients, RCyD showed an ORR of 83%, a 2-year PFS rate of 67%, and a 2-year OS rate of 81% with a median follow-up of 23.4 months. 30 In the recent update of this study, time-to-treatment failure was 35 months, and many of the relapsing patients were still sensitive to rituximab-based regimens. The 8-year OS rates were 100%, 55%, and 27% for the the low-, intermediate-, and high-risk groups, respectively. 31 In a randomized trial with 48 treatment-naive patients with WM who were randomly assigned to either cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or rituximab-CHOP (R-CHOP), R-CHOP showed significantly higher ORR (91% vs. 60%; P ¼ .0188) and 2-year PFS rate (78% vs. 47%; P ¼ .0241). 32 However, a phase III randomized trial comparing BR versus R-CHOP in the indolent lymphomas, including 41 patients with WM, showed significantly longer median 33 In a study by Treon and colleagues with 43 patients with WM (27 treatmentnaive and 16 treated patients), a rituximab and fludarabine combination treatment significantly reduced the median BM involvement (55% vs. 5%; P < .001) and serum IgM protein level (3840 mg/dL vs. 443 mg/dL; P < .001). 34 The ORR in treatmentnaive patients in this study was 96.3%, and the 2-year PFS rate was 67%, with a median follow-up of 40.3 months. 34 In an additional study with 43 treatment-naïve patients with WM, a combination regimen of rituximab, fludarabine, cyclophosphamide, and rituximab (FCR) showed an ORR and a 2-year OS rate of 79% and 69.1%, respectively. 35 A recent retrospective study with FCR in 27 treatment-naïve patients with WM showed an ORR of 76% and a major response rate (MRR) of 88%, with 3-year PFS and OS rates of 96%. 36 Despite its proven efficacy as front-line and salvage therapies, fludarabine-containing regimens are preferably recommended for relapsed or refractory patients owing to prolonged cytopenia associated with fludarabine as well as a high risk (10%-15%) of secondary malignancies including myelodysplastic syndrome or acute myeloid leukemia. However, nucleoside analogs, such as fludarabine or bendamustine, have an important role in central nervous system (CNS) involvement such as Bing-Neel syndrome because they have good CNS penetration compared with other classes of drugs. 37 The efficacy of proteasome inhibitors has been extensively studied in patients with MM. 38 In a study by Ghobrial et al with 26
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treatment-naïve patients with WM, 6 cycles of bortezomib combined with rituximab showed an ORR 100% and 1-year PFS and OS rates of 75% and 96%, respectively. 39 A RCyD combination showed a median PFS of 35 months and a 5-year OS rate of 62%. 28, 31 Similar to RCyD, a bortezomib, dexamethasone, and rituximab (BDR) combination in 2 studies showed an ORR of 90% to 96%, a PFS rate of 40% to 80%, and an OS rate of 80% to 100% with significant improvement in BM involvement and serum IgM levels. 40, 41 In these studies, PN was the most common toxicity, rendering 8% to 61% patients to discontinue bortezomib. 40, 41 Carfilzomib, a second-generation proteasome inhibitor, was shown to have a substantively low rate of PN compared with bortezomib in MM trials. 42 In a phase II trial with patients with WM who received no more than 1 prior therapy, carfilzomib, rituximab, and dexamethasone (KRD) showed an ORR of 87%, regardless of MYD88 or CXCR4 mutational status, with no reported grade 3 PN. 43 
Evidence in Relapsed or Refractory Disease
Anti-CD20 monoclonal antibodies were shown to be effective in patients with WM with relapsed or refractory disease (Table 3) . In 2 studies, patients with relapsed WM who received rituximab for 4 to 8 cycles yielded an ORR of 30% to 40%. 25, 44 Similarly, relapsed patients with WM achieved an ORR of 57% with ofatumumab treatment. 29 Anti-CD20 monoclonal antibodies in combination with bendamustine or fludarabine showed better efficacy compared with anti-CD20 monotherapy. In a retrospective study with 30 patients with WM with relapsed or refractory disease, bendamustine combined with either rituximab or ofatumumab demonstrated an ORR of 83.3% with significant improvement in serum IgM level (3980 mg/dL vs. 698 mg/dL). 45 Also, rituximab combined with Bortezomib also demonstrated clinical efficacy in refractory or relapsed patients with WM. In a study by Dimopoulos et al, 60% of patients achieved PR with bortezomib. 46 Also, bortezomib significantly reduced the median serum IgM level (4460 mg/dL vs. 2092 mg/dL) as well as BM involvement (30% vs. 20%), as shown in a study by Treon et al. 47 In this study, the ORR and MRR were 48%
and 85%, respectively, and 6 of the 23 responding patients remained progression-free (PFS rate, 26%) with a median follow-up of 18.2 months. 47 Moreover, bortezomib combined with rituximab in 37 relapsed patients showed an ORR of 62%, a 1-year PFS of 58%, and a 1-year OS of 94%. 48 Ibrutinib has also been studied in patients with WM, as data with MYD88 L265P leads to constitutively active BTK signaling. 49 In a recent phase II trial with 66 patients with WM with prior treatments, ibrutinib showed an ORR of 73%, a 2-year PFS rate of 69.1%, and an OS rate of 95.2%. 50 Also, the median BM involvement (60% vs. 25%) and serum IgM levels (3520 mg/dL vs. 880 mg/dL) significantly improved upon ibrutinib treatment. The best serum IgM and hemoglobin responses were achieved in MYD88 L265P /CXCR4 WT patients, whereas the least responses were seen in MYD88 WT /CXCR4 WT patients. 50 Based on these results, the United States Food and Drug Administration has approved ibrutinib for patients with WM. Common adverse reactions associated with ibrutinib include cytopenia, fatigue, diarrhea, bruising, and rash. 50 Ibrutinib has also been shown to increase the risk of atrial fibrillation and bleeding, although the incidence is low. 51 Current studies are assessing the prognostic impact of MYD88 and CXCR4 mutations and correlative outcomes. A larger study evaluating 175 patients with WM showed significantly higher BM involvement and serum IgM levels in patients harboring MYD88
L265P and CXCR4 nonsense mutation compared with those with MYD88 L265P and CXCR4 frameshift mutation or MYD88 L265P and CXCR4
WT52
. Surprisingly, patients with MYD88 L265P showed significantly worse OS compared with patients with MYD88 WT despite their lower disease burden. 52 In a recent study comparing whole genome sequencing in 57 patients with WM versus healthy donors, MYD88 and CXCR4 expression levels were shown to be inversely correlated, which is also affected by mutation status. 53 In most of the patients with WM, DNTT, RAG1, and RAG2, which are involved in VDJ recombination, and BCL2 were found to be highly upregulated, and BAX expression was low. 53 Further, in comparison to patients with MYD88 L265P , patients with MYD88 WT showed increased expression of PI3K
signaling genes, but low NFkB response genes as well as increased promoter methylation in PRDM5 and WNK2 genes. 53 Collectively, these findings suggest that BCL2, PI3K inhibitors, and hypomethylating agents may be effective in WM.
Immunomodulatory agents and mTOR inhibitors have also been studied in WM. Combination therapy of lenalidomide and rituximab showed an ORR of 50% and a PFS rate of 25% with significant improvement in serum IgM level (2980 mg/dL vs. 1775 mg/dL; P ¼ .015). 54 One of the caveats in the study was that tolerance was a limiting factor for treatment as lenalidomide causes A total of 25 patients had no prior treatment in this study.
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Clinical Lymphoma, Myeloma & Leukemia May 2017 -259 noticeable toxicities, including cytopenia from myelosuppression. The mTOR inhibitors were shown to be effective in NHLs, [55] [56] [57] [58] [59] [60] and a preclinical study showed that PI3K/AKT/mTOR pathway is activated in WM. 61 In a phase II study with everolimus 10 mg/ day, 42% and 28% of patients achieved PR and MR, respectively, with an ORR of 70%. The estimated PFS rates at 6 and 12 months were 75% and 62%, respectively, although 56% of patients experienced grade 3 toxicities, requiring dose reduction or treatment delay. 62, 63 In a subsequent phase I/II trial with 46 patients, combination regimen of everolimus, bortezomib, and rituximab followed by everolimus maintenance therapy showed a CR in 6% and an MR in 89% of patients. 64 In this study, 82% of patients completed 6 cycles of combination therapy; however, 52% of patients required everolimus dose reduction or interruption during treatment. In patients who did not have dose alteration and received the full dose during their treatment cycles, the median PFS was 21 months. 64 Of note, there are significant discordance between IgM and BM responses, indicating the importance of a BM exam for the treatment response when patients are treated with everolimus. 64 
SCT
Although there is not enough data, SCT could be an option for patients with refractory disease as salvage therapy. Autologous SCT in the European Bone Marrow Transplant Registry (EBMTR) study with 155 patients with WM showed 5-year PFS and OS rates of 49% and 69%, respectively, and a nonrelapsed mortality of 5.6%. 65 Allogeneic SCT reported by EBMTR showed 5-year PFS and OS rates of 56% and 62%, respectively, in patients who received myeloablative conditioning versus 49% and 64% in reducedintensity conditioning regimens. 66 
Recommendations
Asymptomatic patients with WM can be managed with watchful waiting, and only symptomatic patients need treatment. In patients with a high IgM level (more than 4 g/dL) or hyperviscosity symptoms, plasmapheresis should be immediately performed. Plasmapheresis should then be followed by cytoreductive treatment.
In treatment-naive patients, rituximab mono-or combination therapy provides a reasonable option for first-line therapy. Rituximab as a single agent can lead to IgM flare, and the response rate is lower than combination therapy. Accordingly, it is contraindicated in patients with significantly high IgM levels but can be considered in frail patients who cannot tolerate combination therapy. In rituximab-based combination regimens, RCyD and BR are both highly effective and well-tolerated in elderly patients. Also, BR has lower myelosuppression compared with other purine analogs. Nucleotide analogs in general may increase the risk of secondary malignancies; therefore, it should be avoided in younger patients. Proteasome inhibitor-based regimens are recommended in patients with paraprotein-related symptoms, including hyperviscosity, cryoglobulinemia, cold agglutinemia, and amyloidosis. Although carfilzomib is favored as a neuropathy-sparing agent compared with bortezomib, it was shown to increase the risk of cardiac toxicity, and it should be avoided in patients with underlying cardiovascular comorbidity. Ibrutinib is approved as the first-line therapy in treatment-naive patients. Once treatment is started, patients should continue ibrutinib until they develop intolerance or disease progression. At this point, there is a lack of long-term safety data. Therefore, it is favorably used in patients who are not able or not willing to receive cytotoxic therapy. Although there is no consensus regarding the role of maintenance therapy, rituximab was shown to have a PFS benefit in a retrospective study in a maintenance setting. 67 This still remains to be tested in a prospective study, and the question of optimal regimens also remains to be answered. Previously treated patients with WM with relapsed disease can be retreated with initial regimens as long as they had an initial response of more than 2 years. Rituximab late intolerance may occur in 10% to 15% of patients, and ofatumumab can be an alternative option in these cases. Nucleotide analogs such as a fludarabine-based regimen can be considered in fit patients, and ibrutinib is a good option. mTOR inhibitors and immune modulatory agents could be an alternative option for treatment in the refractory setting. Lastly, autologous and allogeneic SCT can be an alternative option in selected patients.
Future Perspective
There are a number of active clinical trials investigating the use of chemotherapy and other targeted therapy drugs. Therapies that are currently being investigated through phase II clinical trials include single or combination therapies of monoclonal antibodies, proteasome inhibitors, immunomodulatory agents, PI3K/Akt/mTOR pathway inhibitors, BTK inhibitors, and a histone deacetylase inhibitor, whereas others are still in the early developmental stages. 28 
Conclusion
Traditionally, many of the WM treatment regimens have been adopted from those of MM and NHLs. MYD88 L265P and CXCR4 somatic mutations are newly identified in patients with WM. Accordingly, a new therapy, such as ibrutinib, was shown to be effective in patients with WM, and currently there are many ongoing clinical trials with combination regimens. Given the lack of randomized controlled trials, there is no standard of care established, and most of the recommendations are based on phase II clinical trials and expert opinion. The treatment choice should be tailored to the individual patient, considering the necessity for rapid cytoreduction, presence of viscosity-related symptoms, comorbidity, sideeffects of each agent, eligibility for SCT, and goal of treatment.
